KR100735506B1 - 결장에서 방출시키기 위한 다층 약제학적 생성물 - Google Patents
결장에서 방출시키기 위한 다층 약제학적 생성물 Download PDFInfo
- Publication number
- KR100735506B1 KR100735506B1 KR1020017014566A KR20017014566A KR100735506B1 KR 100735506 B1 KR100735506 B1 KR 100735506B1 KR 1020017014566 A KR1020017014566 A KR 1020017014566A KR 20017014566 A KR20017014566 A KR 20017014566A KR 100735506 B1 KR100735506 B1 KR 100735506B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- active ingredient
- copolymer
- hours
- methacrylic acid
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
으로 필수적으로 이루어지고,
여기서, pH 1.2에서 2시간 동안 및 후속적으로 완충제를 변화시켜 pH 7.0으로 조절하는 USP 방출 시험에서, 존재하는 활성 성분이 시험 시작 후 2.0시간까지는 5% 미만 방출되고 시험 시작 후 8시간에서는 30 내지 80% 방출되는,
다층 약물 형태를 사용함으로써 해결된다.
실시예 2: 비율이 6.8:3.2인 EUDRAGITR RS와 EUDRAGITR RL과의 혼합물로 이루어지고 층 두께가 6.8중량%인 내부 피막 및 EUDRAGITR FS로 이루어지고 층 두께가 14중량%인 외부 피막.
실시예 3: 비율이 8:2인 EUDRAGITR RS와 EUDRAGITR RL과의 혼합물로 이루어지고 층 두께가 5중량%인 내부 피막 및 EUDRAGITR FS로 이루어지고 층 두께가 20중량%인 외부 피막.
Claims (8)
- (a) 약제학적 활성 성분을 함유하는 코어,(b) 아크릴산 또는 메타크릴산의 유리 라디칼 중합된 C1-C4 알킬 에스테르 85 내지 98중량% 및 알킬 라디칼에 4급 암모늄 그룹을 갖는 (메트)아크릴레이트 단량체 15 내지 2중량%로 이루어진 공중합체 또는 공중합체들의 혼합물로 이루어진 내부 피막 및(c) 아크릴산 또는 메타크릴산의 유리 라디칼 중합된 C1-C4 알킬 에스테르 75 내지 95중량% 및 알킬 라디칼에 음이온성 그룹을 갖는 (메트)아크릴레이트 단량체 5 내지 25중량%로 이루어진 공중합체로 이루어진 외부 피막으로 필수적으로 이루어지며,여기서, pH 1.2에서 2시간 동안 및 후속적으로 완충제를 변화시켜 pH 7.0으로 조절하는 USP 방출 시험에서, 존재하는 활성 성분이 시험 시작 후 2.0시간까지는 5% 미만 방출되고 시험 시작 후 8시간에서는 30 내지 80% 방출되는,다층 약물 형태.
- 제1항에 있어서, 약제학적 활성 성분이 아미노살리실레이트, 설폰아미드 또는 글루코코르티코이드임을 특징으로 하는 다층 약물 형태.
- 제2항에 있어서, 약제학적 활성 성분이 5-아미노살리실산, 올살라진, 설팔라진, 프레드니손 또는 부데소나이드임을 특징으로 하는 다층 약물 형태.
- 제1항 내지 제3항 중의 어느 한 항에 있어서, 내부 피막의 층 두께가, 약제학적 활성 성분을 함유하는 코어의 중량을 기준으로 하여, 2 내지 50중량%임을 특징으로 하는 다층 약물 형태.
- 제1항 내지 제3항 중의 어느 한 항에 있어서, 외부 피막의 층 두께가, 약제학적 활성 성분을 함유하는 코어 및 내부 피막의 중량을 기준으로 하여, 5 내지 50중량%임을 특징으로 하는 다층 약물 형태.
- 제1항 내지 제3항 중의 어느 한 항에 있어서, 내부 피막이 아크릴산 또는 메타크릴산의 유리 라디칼 중합된 C1-C4 알킬 에스테르 93 내지 98중량%와 2-트리메틸암모늄에틸 메타크릴레이트 클로라이드 7 내지 2중량%의 공중합체와 아크릴산 또는 메타크릴산의 유리 라디칼 중합된 C1-C4 알킬 에스테르 85 내지 93중량% 미만과 2-트리메틸암모늄에틸 메타크릴레이트 클로라이드 7 이상 내지 15중량%의 공중합체의 혼합물임을 특징으로 하는 다층 약물 형태.
- 제6항에 있어서, 공중합체 혼합물의 혼합비가 20:1 내지 1:20임을 특징으로 하는 다층 약물 형태.
- 제1항 내지 제3항 중의 어느 한 항에 있어서, 정제, 펠렛, 펠렛으로부터 압축된 정제, 또는 캡슐에 팩킹된 펠렛 형태임을 특징으로 하는 다층 약물 형태.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10013029A DE10013029A1 (de) | 2000-03-17 | 2000-03-17 | Mehrschichtige Arzneiform für die Colonfreigabe |
DE10013029.1 | 2000-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010114268A KR20010114268A (ko) | 2001-12-31 |
KR100735506B1 true KR100735506B1 (ko) | 2007-07-06 |
Family
ID=7635100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017014566A KR100735506B1 (ko) | 2000-03-17 | 2001-03-09 | 결장에서 방출시키기 위한 다층 약제학적 생성물 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6632454B2 (ko) |
EP (1) | EP1178781B1 (ko) |
JP (1) | JP4707918B2 (ko) |
KR (1) | KR100735506B1 (ko) |
CN (1) | CN1193743C (ko) |
AT (1) | ATE305294T1 (ko) |
AU (1) | AU3928501A (ko) |
BR (1) | BR0105102A (ko) |
CA (1) | CA2373909C (ko) |
DE (2) | DE10013029A1 (ko) |
ES (1) | ES2248292T3 (ko) |
HK (1) | HK1048067A1 (ko) |
IL (1) | IL146068A (ko) |
MX (1) | MXPA01011444A (ko) |
PL (1) | PL200211B1 (ko) |
SK (1) | SK285367B6 (ko) |
WO (1) | WO2001068058A1 (ko) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10220470A1 (de) * | 2002-04-30 | 2003-11-20 | Roehm Gmbh | ph-sensitives Polymer |
DE19961334A1 (de) * | 1999-12-17 | 2001-06-21 | Roehm Gmbh | Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere |
DE10011447A1 (de) * | 2000-03-10 | 2001-09-20 | Roehm Gmbh | Dispersion mit nichtionischem Emulgator |
CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
DE10127134A1 (de) * | 2001-06-05 | 2002-12-12 | Roehm Gmbh | verfahren zur Herstellung von Formkörpern aus (Meth)acrylat-Copolymeren mittels Spritzguß |
DE10151290A1 (de) * | 2001-10-22 | 2003-04-30 | Roehm Gmbh | Verfahren zur Herstellung von wirkstoffhaltigen Pellets |
US20030118329A1 (en) * | 2001-12-21 | 2003-06-26 | Pere Obrador | Video indexing using high resolution still images |
DE10208335A1 (de) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
DE10214002A1 (de) * | 2002-03-27 | 2003-10-09 | Roehm Gmbh | Pharmazeutische Formulierung für den Wirkstoff Budesonid |
ZA200501508B (en) * | 2002-09-03 | 2006-10-25 | Biovail Lab Inc | Pharmaceuticals formulations and methods for modified release of statin drugs |
MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
DE10250543A1 (de) * | 2002-10-29 | 2004-05-19 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
MXPA04010956A (es) * | 2003-01-30 | 2005-01-25 | Roehm Gmbh | Forma de dosis farmaceutica y metodo para la produccion de la misma. |
MXPA05008409A (es) | 2003-02-10 | 2005-10-05 | Elan Pharm Inc | Formulacion de inmunoglobulina y metodo para la preparacion de la misma. |
WO2005002549A1 (en) * | 2003-07-04 | 2005-01-13 | Nycomed Danmark Aps | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
US7825106B2 (en) * | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
US7737133B2 (en) * | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
CA2553775A1 (en) * | 2004-01-20 | 2005-08-11 | Richard F. Harty | Compositions and methods of treatment for inflammatory diseases |
DE102004035936A1 (de) * | 2004-07-23 | 2006-03-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
US20060078621A1 (en) * | 2004-10-13 | 2006-04-13 | Wedinger Robert S | Method of providing customized drug delivery systems |
RU2401125C2 (ru) | 2004-12-27 | 2010-10-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ стабилизации лекарственного средства против деменции |
EP1868580A1 (en) * | 2005-03-29 | 2007-12-26 | Evonik Röhm GmbH | Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance |
ES2429095T3 (es) * | 2005-05-18 | 2013-11-13 | Da Volterra | Aporte colónico de adsorbentes |
DE102005024614A1 (de) * | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
FR2894143B1 (fr) * | 2005-12-01 | 2008-05-02 | Pierre Fabre Medicament Sa | Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation. |
US20090068263A1 (en) * | 2006-04-20 | 2009-03-12 | Themis Laboratories Private Limited | Multiple unit compositions |
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
PL1880718T3 (pl) * | 2006-07-10 | 2012-02-29 | Dr R Pfleger Chemische Fabrik Gmbh | Preparat farmaceutyczny do podawania doustnego o kontrolowanym uwalnianiu w jelicie cienkim i sposób jego wytwarzania |
DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
CN100555000C (zh) * | 2007-03-12 | 2009-10-28 | 中国矿业大学 | 一种非接触式矿山压力观测及评价方法 |
WO2008117814A1 (ja) * | 2007-03-26 | 2008-10-02 | Teikoku Seiyaku Co., Ltd. | 大腸送達用経口製剤 |
US20090036414A1 (en) * | 2007-08-02 | 2009-02-05 | Mutual Pharmaceutical Company, Inc. | Mesalamine Formulations |
DE102007060175A1 (de) * | 2007-12-13 | 2009-06-18 | Johannes Gutenberg-Universität Mainz | Quartärnisierung des Zusatzstoffs Aminoalkyl Methacrylat Copolymer E zur Verbesserung der Permeabilität und Löslichkeit von Arzneistoffen |
TR201902212T4 (tr) * | 2008-01-10 | 2019-06-21 | Evonik Roehm Gmbh | Geli̇şmi̇ş deği̇şken dozlu akti̇f madde salimina sahi̇p kapli farmasöti̇k veya nutrasöti̇k preparat |
SI2230932T1 (sl) * | 2008-01-10 | 2017-07-31 | Evonik Roehm Gmbh | Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu |
US20110070302A2 (en) * | 2008-01-10 | 2011-03-24 | Evonik Roehm Gmbh | Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release |
BRPI0915411A2 (pt) * | 2008-06-26 | 2015-11-03 | Mcneil Ppc Inc | partículas revestidas contendo agentes farmaceuticamente ativos |
IT1395143B1 (it) * | 2009-08-06 | 2012-09-05 | Sofar Spa | Composizioni granulari a rilascio controllato di mesalazina e processo per il loro ottenimento. |
EP2501368B1 (en) * | 2009-11-16 | 2018-04-18 | Evonik Röhm GmbH | A process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent |
WO2012171575A1 (en) * | 2011-06-17 | 2012-12-20 | Evonik Röhm Gmbh | Coating composition suitable for pharmaceutical or nutraceutical dosage forms |
EP2659881B1 (en) * | 2012-04-30 | 2017-11-29 | Tillotts Pharma Ag | A delayed release drug formulation |
TWI688411B (zh) * | 2013-02-22 | 2020-03-21 | 日商志瑞亞新藥工業股份有限公司 | 腸溶錠 |
WO2014154677A1 (en) * | 2013-03-25 | 2014-10-02 | Ferring Bv | Composition for the treatment of disease |
MA38847B2 (fr) * | 2013-10-29 | 2021-02-26 | Tillotts Pharma Ag | Formulation médicamenteuse à libération retardée |
CN106132435B (zh) | 2014-02-07 | 2021-08-27 | 亚洲大学校产学协力团 | 筛选通过促进rip3表达增强抗癌药物的敏感性的抗癌辅剂的方法和试剂盒 |
EP3154523B1 (en) | 2014-06-16 | 2018-11-21 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
CA2959186C (en) | 2014-09-19 | 2020-03-24 | The Procter & Gamble Company | Pulsed release phenylephrine dosage forms |
CA3018328A1 (en) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
MX2017015465A (es) | 2015-06-05 | 2018-03-28 | Evonik Roehm Gmbh | Composicion farmaceutica o nutraceutica con resistencia contra la influencia del etanol. |
WO2017173068A1 (en) * | 2016-03-30 | 2017-10-05 | University Of Maryland, Baltimore | Microparticulate system for colonic drug delivery |
US10278930B2 (en) | 2017-03-16 | 2019-05-07 | The Procter & Gamble Company | Method for relieving sinus congestion |
CN108836948B (zh) * | 2018-06-11 | 2024-04-12 | 宁波西敦医药包衣科技有限公司 | 一种利用包衣技术实现营养素可控制释放的产品 |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19741114A1 (de) * | 1997-09-12 | 1999-03-18 | Gerold Dr Lukowski | Feuchtigkeitsstabile und magensaftresistente Arzneiformen für Tiere |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US6156340A (en) * | 1996-03-29 | 2000-12-05 | Duquesne University Of The Holy Ghost | Orally administrable time release drug containing products |
DE19845358A1 (de) * | 1998-10-02 | 2000-04-06 | Roehm Gmbh | Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe |
CN1202815C (zh) * | 1999-08-31 | 2005-05-25 | 格吕伦塔尔有限公司 | 含有曲马朵糖精盐的持续释放给药剂型 |
-
2000
- 2000-03-17 DE DE10013029A patent/DE10013029A1/de not_active Withdrawn
-
2001
- 2001-03-09 IL IL146068A patent/IL146068A/en active IP Right Grant
- 2001-03-09 CN CNB018005551A patent/CN1193743C/zh not_active Expired - Lifetime
- 2001-03-09 PL PL350888A patent/PL200211B1/pl unknown
- 2001-03-09 DE DE50107551T patent/DE50107551D1/de not_active Expired - Lifetime
- 2001-03-09 MX MXPA01011444A patent/MXPA01011444A/es active IP Right Grant
- 2001-03-09 CA CA002373909A patent/CA2373909C/en not_active Expired - Lifetime
- 2001-03-09 SK SK1627-2001A patent/SK285367B6/sk not_active IP Right Cessation
- 2001-03-09 BR BR0105102-4A patent/BR0105102A/pt not_active Application Discontinuation
- 2001-03-09 ES ES01913856T patent/ES2248292T3/es not_active Expired - Lifetime
- 2001-03-09 JP JP2001566622A patent/JP4707918B2/ja not_active Expired - Lifetime
- 2001-03-09 US US09/926,567 patent/US6632454B2/en not_active Expired - Lifetime
- 2001-03-09 WO PCT/EP2001/002678 patent/WO2001068058A1/de active IP Right Grant
- 2001-03-09 KR KR1020017014566A patent/KR100735506B1/ko active IP Right Grant
- 2001-03-09 EP EP01913856A patent/EP1178781B1/de not_active Expired - Lifetime
- 2001-03-09 AT AT01913856T patent/ATE305294T1/de active
- 2001-03-09 AU AU39285/01A patent/AU3928501A/en not_active Abandoned
-
2003
- 2003-01-07 HK HK03100158A patent/HK1048067A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19741114A1 (de) * | 1997-09-12 | 1999-03-18 | Gerold Dr Lukowski | Feuchtigkeitsstabile und magensaftresistente Arzneiformen für Tiere |
Also Published As
Publication number | Publication date |
---|---|
HK1048067A1 (en) | 2003-03-21 |
CA2373909A1 (en) | 2001-09-20 |
BR0105102A (pt) | 2002-02-19 |
SK16272001A3 (sk) | 2002-08-06 |
AU3928501A (en) | 2001-09-24 |
MXPA01011444A (es) | 2003-09-10 |
JP2003526655A (ja) | 2003-09-09 |
CN1364077A (zh) | 2002-08-14 |
DE50107551D1 (de) | 2005-11-03 |
ES2248292T3 (es) | 2006-03-16 |
EP1178781B1 (de) | 2005-09-28 |
ATE305294T1 (de) | 2005-10-15 |
IL146068A (en) | 2007-02-11 |
WO2001068058A1 (de) | 2001-09-20 |
DE10013029A1 (de) | 2001-09-20 |
EP1178781A1 (de) | 2002-02-13 |
IL146068A0 (en) | 2002-07-25 |
CA2373909C (en) | 2009-12-22 |
PL200211B1 (pl) | 2008-12-31 |
KR20010114268A (ko) | 2001-12-31 |
CN1193743C (zh) | 2005-03-23 |
JP4707918B2 (ja) | 2011-06-22 |
US20020192282A1 (en) | 2002-12-19 |
US6632454B2 (en) | 2003-10-14 |
PL350888A1 (en) | 2003-02-10 |
SK285367B6 (sk) | 2006-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100735506B1 (ko) | 결장에서 방출시키기 위한 다층 약제학적 생성물 | |
JP5502254B2 (ja) | 少なくとも2種類の異なる被覆ペレット形から成る多粒子剤形 | |
KR101973235B1 (ko) | 에탄올의 영향에 대해 지속 방출 특성 및 내성을 갖는 제약 또는 기능식품 조성물 | |
JP5675100B2 (ja) | 多層の分離層を有する薬剤形 | |
KR101200286B1 (ko) | 활성성분 부데소니드용 약제학적 제형 | |
KR101387835B1 (ko) | 코팅된 제약 제형을 제조하기 위한 중합체 혼합물의 용도및 혼합된 중합체성 코팅을 갖는 제약 제형 | |
JP5193036B2 (ja) | 低められたpH‐値で作用物質を放出する薬剤形を製造するための被覆として、部分中和された陰イオン(メタ)アクリレートコポリマーの使用 | |
KR101873075B1 (ko) | 하나 이상의 알긴산 염을 포함하는 위 내성 제약 또는 건강기능식품 제제 | |
KR101739166B1 (ko) | 다층형 약제 | |
JP5847303B2 (ja) | 医薬品剤形又は機能性食品剤形に適したコーティング組成物 | |
JP2008534531A (ja) | 調節物質の送達に影響を及ぼすマトリックスを有するペレットを有する多粒子の医薬剤形 | |
KR20050083847A (ko) | 중성 코어와 메타크릴레이트 공중합체 및 메타크릴레이트단량체로 이루어진 내부 및 외부 피복물을 포함하는, 활성물질 함유 다층 투여 형태 | |
JP2008534530A (ja) | 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形 | |
JP2015528450A (ja) | エタノールの影響に対して耐性を有する胃液抵抗性の医薬組成物又は栄養補助組成物 | |
KR20060121182A (ko) | 활성 성분의 방출에 대하여 조절 방식으로 작용하는 물질을함유하는 다층 약제학적 투여 형태 | |
KR20170086044A (ko) | 에탄올의 영향에 대해 내성을 갖는 의약품 또는 영양보조식품 조성물 | |
KR20160115995A (ko) | 지속 방출 특성을 가지며 에탄올의 영향에 대한 저항성을 갖는 약제학적 또는 건강기능성 조성물 | |
JP2005506991A (ja) | 作用物質としてペプチド又はタンパク質を含有する医薬形を製造するためのコポリマーの使用 | |
JP2021515778A (ja) | エタノールの影響に対する耐性を有するポリマー混合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130620 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140619 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150619 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160616 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170616 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190620 Year of fee payment: 13 |